Morgan Stanley’s Arcadia Biosciences RKDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3 Hold
2
﹤0.01% 8249
2025
Q4
$4 Sell
2
-606
-100% -$2.23K ﹤0.01% 8164
2025
Q3
$2.11K Sell
608
-179
-23% -$731 ﹤0.01% 7294
2025
Q2
$3.39K Buy
787
+179
+29% +$707 ﹤0.01% 7128
2025
Q1
$1.81K Buy
608
+1
+0.2% +$4 ﹤0.01% 7193
2024
Q4
$3.59K Hold
607
﹤0.01% 7087
2024
Q3
$1.66K Hold
607
﹤0.01% 7165
2024
Q2
$1.91K Buy
607
+400
+193% +$1.01K ﹤0.01% 7073
2024
Q1
$457 Sell
207
-207
-50% -$537 ﹤0.01% 7246
2023
Q4
$1.3K Buy
414
+207
+100% +$648 ﹤0.01% 7178
2023
Q3
$693 Sell
207
-6
-3% -$25 ﹤0.01% 7273
2023
Q2
$826 Sell
213
-5
-2% -$27 ﹤0.01% 7326
2023
Q1
$1.63K Buy
218
+6
+3% +$64 ﹤0.01% 7275
2022
Q4
$2.3K Hold
212
﹤0.01% 7332
2022
Q3
$4K Sell
212
-63
-23% -$2.15K ﹤0.01% 7317
2022
Q2
$11K Sell
275
-163
-37% -$7.5K ﹤0.01% 7189
2022
Q1
$24K Sell
438
-518
-54% -$24.7K ﹤0.01% 7075
2021
Q4
$39K Buy
956
+16
+2% +$1.04K ﹤0.01% 6925
2021
Q3
$78K Sell
940
-22
-2% -$2.06K ﹤0.01% 6502
2021
Q2
$114K Buy
962
+880
+1,073% +$95.9K ﹤0.01% 6299
2021
Q1
$9K Buy
82
+80
+4,000% +$9.81K ﹤0.01% 6984
2020
Q4
$0 Sell
2
-25
-93% -$3.05K ﹤0.01% 7099
2020
Q3
$3K Sell
27
-278
-91% -$37.5K ﹤0.01% 6522
2020
Q2
$46K Sell
305
-42
-12% -$6.53K ﹤0.01% 5702
2020
Q1
$40K Buy
347
+76
+28% +$13.2K ﹤0.01% 5556
2019
Q4
$59K Buy
271
+215
+384% +$43.1K ﹤0.01% 5807
2019
Q3
$11K Sell
56
-1,982
-97% -$380K ﹤0.01% 6175
2019
Q2
$250K Buy
2,038
+2,037
+203,700% +$433K ﹤0.01% 4934
2019
Q1
$0 Hold
1
﹤0.01% 6685
2018
Q4
$0 Sell
1
-54
-98% -$9.08K ﹤0.01% 6708
2018
Q3
$10K Buy
55
+54
+5,400% +$13.6K ﹤0.01% 6307
2018
Q2
$0 Buy
+1
New +$546 ﹤0.01% 6733
2017
Q3
Sell
-1
Closed 6594
2017
Q2
$0 Buy
+1
New +$558 ﹤0.01% 6638
2016
Q3
Sell
-1
Closed -$1K 6553
2016
Q2
$1K Buy
+1
New +$1.67K ﹤0.01% 6440
2016
Q1
Hold
0
-$1K 6685
2015
Q4
Sell
-1
Closed -$2.6K 6574
2015
Q3
$3K Buy
+1
New +$4.16K ﹤0.01% 6451
2015
Q2
Hold
0
6576

Other funds holding RKDA

Morgan Stanley's RKDA Position: Q1 2026 in Review

Morgan Stanley held its Arcadia Biosciences (RKDA) position steady in Q1 2026 at 2 shares worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #8249.

Morgan Stanley first reported a position in RKDA in Q3 2015 and has held it in 35 quarters since. The position peaked at $250K in Q2 2019. 16 funds tracked by Wall St. Rank hold RKDA as of Q1 2026.

  • Morgan Stanley held 2 shares of Arcadia Biosciences worth $3 as of Q1 2026.
  • Morgan Stanley left its Arcadia Biosciences share count unchanged in Q1 2026.
  • Arcadia Biosciences made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8249 holding.
  • Morgan Stanley first reported a position in Arcadia Biosciences in Q3 2015 and has held it in 35 quarters since.
  • Morgan Stanley's Arcadia Biosciences position peaked at $250K in Q2 2019.
  • 16 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.